NIKKEI 225
39,069.68 +282.30 (+0.73%) HANG SENG
19,636.22 +82.61 (+0.42%) CRUDE OIL
79.65 -0.15 (-0.19%) GOLD FUTURES
2,431.90 -6.60 (-0.27%) DOW
39,806.77 -196.82 (-0.49%) Bitcoin GBP
54,859.75 +2,627.66 (+5.03%)
ANVS May 2024 10.000 put
| Previous close | 1.9500 |
| Open | 2.7000 |
| Bid | 1.6500 |
| Ask | 2.2000 |
| Strike | 10.00 |
| Expiry date | 2024-05-17 |
| Day's range | 1.7000 - 2.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.91k |
ZacksAmgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
ZacksKodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
GlobeNewswireAnnovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results. Clinical Updates AD Phase II/III Study On April 29, Annovis announced statistically significant Phase II/III data in patients with early Alzheimer’s disease (AD). Significantly higher rate of improveme
